Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07437404
PHASE3

Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.

Sponsor: Sinocelltech Ltd.

View on ClinicalTrials.gov

Summary

This is an Open Label, Uncontrolled Study to Evaluate the the Safety and Efficacy of SCT800 for Prophylaxis Treatment in Severe Previously Untreated Hemophilia Patients.

Official title: An Open Label, Uncontrolled Study to Evaluate the the Safety and Efficacy of SCT800 for Prophylaxis Treatment in Severe Previously Untreated Hemophilia Patients.

Key Details

Gender

MALE

Age Range

Any - 6 Years

Study Type

INTERVENTIONAL

Enrollment

36

Start Date

2024-04-26

Completion Date

2028-12-26

Last Updated

2026-02-27

Healthy Volunteers

No

Conditions

Interventions

DRUG

SCT800 prophylaxis and treatment for bleeding events

For prophylaxis, 15-50 IU/kg SCT800 is intravenously. For control of bleeding events(BE), 10-20 IU/kg for mild BE, 15 -30IU/kg for moderate BE, 30-50IU/kg for severe BE.

Locations (1)

Beijing children's hospital

Beijing, Beijing Municipality, China